Analysts Anticipate Johnson & Johnson (NYSE:JNJ) Will Announce Earnings of $1.98 Per Share

Brokerages forecast that Johnson & Johnson (NYSE:JNJ) will announce earnings of $1.98 per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Johnson & Johnson’s earnings. The highest EPS estimate is $2.10 and the lowest is $1.86. Johnson & Johnson reported earnings per share of $2.12 during the same quarter last year, which would suggest a negative year-over-year growth rate of 6.6%. The company is expected to issue its next quarterly earnings report on Tuesday, October 20th.

According to Zacks, analysts expect that Johnson & Johnson will report full-year earnings of $7.85 per share for the current year, with EPS estimates ranging from $7.75 to $7.95. For the next year, analysts anticipate that the business will report earnings of $8.94 per share, with EPS estimates ranging from $8.48 to $9.45. Zacks’ earnings per share averages are an average based on a survey of research analysts that cover Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Thursday, July 16th. The company reported $1.67 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.50 by $0.17. The business had revenue of $18.34 billion for the quarter, compared to analysts’ expectations of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. The business’s revenue for the quarter was down 10.8% compared to the same quarter last year. During the same period in the prior year, the company posted $2.58 EPS.

A number of equities research analysts have issued reports on JNJ shares. Independent Research raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their price target for the stock from $161.00 to $164.00 in a report on Monday, July 20th. SVB Leerink reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Wednesday, July 15th. Bank of America reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, July 20th. Cantor Fitzgerald reissued a “buy” rating and set a $168.00 price objective on shares of Johnson & Johnson in a report on Monday, August 3rd. Finally, Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 price objective for the company. in a report on Tuesday, July 7th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $163.00.

Shares of JNJ stock traded up $0.87 on Friday, hitting $147.78. 3,933,279 shares of the company’s stock traded hands, compared to its average volume of 8,528,353. The company has a debt-to-equity ratio of 0.40, a quick ratio of 0.99 and a current ratio of 1.25. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The company’s fifty day simple moving average is $149.34 and its 200 day simple moving average is $144.18. The stock has a market capitalization of $394.13 billion, a price-to-earnings ratio of 21.61, a P/E/G ratio of 3.32 and a beta of 0.68.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were paid a $1.01 dividend. This represents a $4.04 dividend on an annualized basis and a yield of 2.73%. The ex-dividend date was Monday, August 24th. Johnson & Johnson’s dividend payout ratio is currently 46.54%.

In other news, EVP Kathryn E. Wengel sold 16,115 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the transaction, the executive vice president now directly owns 66,658 shares in the company, valued at approximately $10,233,336.16. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Ashley Mcevoy sold 29,000 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total value of $4,276,630.00. Following the sale, the executive vice president now owns 21,682 shares in the company, valued at $3,197,444.54. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by corporate insiders.

Large investors have recently added to or reduced their stakes in the stock. Altshuler Shaham Ltd acquired a new position in Johnson & Johnson during the 1st quarter valued at approximately $35,000. Lake Point Wealth Management raised its stake in Johnson & Johnson by 144.4% during the 1st quarter. Lake Point Wealth Management now owns 286 shares of the company’s stock valued at $38,000 after acquiring an additional 169 shares in the last quarter. Islay Capital Management LLC bought a new stake in shares of Johnson & Johnson in the 2nd quarter worth $42,000. FAI Wealth Management raised its stake in shares of Johnson & Johnson by 45.9% in the 2nd quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after buying an additional 101 shares in the last quarter. Finally, SeaBridge Investment Advisors LLC raised its position in shares of Johnson & Johnson by 160.0% during the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock worth $46,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 67.44% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Capital gains and your 401(k) or IRA

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.